放射治疗
抗药性
医学
癌症研究
脱甲基酶
免疫疗法
联合疗法
遗传增强
靶向治疗
化疗
肿瘤科
癌症
药理学
内科学
表观遗传学
基因
生物
微生物学
生物化学
作者
Clement Agboyibor,Jianshu Dong,Clement Yaw Effah,Emmanuel Kwateng Drokow,Maxwell Ampomah-Wireko,Waqar Pervaiz,Augustina Sangmor,Xinli Ma,Jian Li,Hong Liu,Pengjun Zhang
标识
DOI:10.1016/j.biopha.2022.113934
摘要
It has been proven that metastatic recurrence and therapeutic resistance are linked. Due to the variability of individuals and tumors, as well as the tumor's versatility in avoiding therapies, therapy resistance is more difficult to treat. Therapy resistance has significantly restricted the clinical feasibility and efficacy of tumor therapy, despite the discovery of novel compounds and therapy combinations with increasing efficacy. In several tumors, lysine specific demethylase 1 (LSD1) has been associated to metastatic recurrence and therapeutic resistance. For researchers to better comprehend how LSD1-mediated tumor therapy resistance occurs and how to overcome it in various tumors, this study focused on the role of LSD1 in tumor recurrence and therapeutic resistance. The importance of therapeutically targeted LSD1 was also discussed. Most gene pathway signatures are related to LSD1 inhibitor sensitivity. However, some gene pathway signatures, especially in AML, negatively correlate with LSD1 inhibitor sensitivity, but targeting LSD1 makes the therapy-resistant tumor sensitive to physiological doses of conventional therapy. We propose that combining LSD1 inhibitor with traditional tumor therapy can help patients attain a complete response and prevent cancer relapse.
科研通智能强力驱动
Strongly Powered by AbleSci AI